120 related articles for article (PubMed ID: 24405493)
1. Changes in PR and QTc intervals after switching from olanzapine to risperidone in patients with stable schizophrenia.
Suzuki Y; Sugai T; Ono S; Sawamura K; Fukui N; Watanabe J; Tsuneyama N; Saito M; Someya T
Psychiatry Clin Neurosci; 2014 May; 68(5):353-6. PubMed ID: 24405493
[TBL] [Abstract][Full Text] [Related]
2. Sex differences in the effect of four second-generation antipsychotics on QTc interval in patients with schizophrenia.
Suzuki Y; Sugai T; Fukui N; Watanabe J; Ono S; Tsuneyama N; Saito M; Someya T
Hum Psychopharmacol; 2013 May; 28(3):215-9. PubMed ID: 23553637
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia.
Hatta K; Otachi T; Fujita K; Morikawa F; Ito S; Tomiyama H; Abe T; Sudo Y; Takebayashi H; Yamashita T; Katayama S; Nakase R; Shirai Y; Usui C; Nakamura H; Ito H; Hirata T; Sawa Y;
Schizophr Res; 2014 Sep; 158(1-3):213-22. PubMed ID: 25086659
[TBL] [Abstract][Full Text] [Related]
4. Dose-dependent effects of olanzapine on QT intervals and plasma prolactin levels in Japanese patients with stable schizophrenia.
Suzuki Y; Ono S; Sugai T; Fukui N; Watanabe J; Tsuneyama N; Sawamura K; Someya T
Hum Psychopharmacol; 2011 Aug; 26(6):440-3. PubMed ID: 21823168
[TBL] [Abstract][Full Text] [Related]
5. Changes in QT interval after switching to quetiapine in Japanese patients with schizophrenia.
Suzuki Y; Sugai T; Fukui N; Watanabe J; Ono S; Tsuneyama N; Saito M; Someya T
Hum Psychopharmacol; 2013 Jan; 28(1):94-6. PubMed ID: 23161621
[TBL] [Abstract][Full Text] [Related]
6. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study.
Sun L; Yagoda S; Xue H; Brown R; Nangia N; McDonnell D; Rege B; von Moltke L; Darpo B
Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jun; 100():109881. PubMed ID: 32004636
[TBL] [Abstract][Full Text] [Related]
7. Increased risk of antipsychotic-related QT prolongation during nighttime: a 24-hour holter electrocardiogram recording study.
Watanabe J; Suzuki Y; Fukui N; Ono S; Sugai T; Tsuneyama N; Someya T
J Clin Psychopharmacol; 2012 Feb; 32(1):18-22. PubMed ID: 22198445
[TBL] [Abstract][Full Text] [Related]
8. Comparative cardiovascular safety of risperidone and olanzapine, based on electrocardiographic parameters and blood pressure: a prospective open label observational study.
Choure BK; Gosavi D; Nanotkar S
Indian J Pharmacol; 2014; 46(5):493-7. PubMed ID: 25298577
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial.
Tunis SL; Faries DE; Nyhuis AW; Kinon BJ; Ascher-Svanum H; Aquila R
Value Health; 2006; 9(2):77-89. PubMed ID: 16626411
[TBL] [Abstract][Full Text] [Related]
10. Absence of Change in Corrected QT Interval in Children and Adolescents Receiving Antipsychotic Treatment: A 12 Month Study.
Alda JA; Muñoz-Samons D; Tor J; Merchán-Naranjo J; Tapia-Casellas C; Baeza I; Calvo-Escalona R; Castro-Fornieles J; Martínez-Cantarero C; Andrés-Nestares P; Fernández-Avilés F; Arango C
J Child Adolesc Psychopharmacol; 2016 Jun; 26(5):449-57. PubMed ID: 26779966
[TBL] [Abstract][Full Text] [Related]
11. A comparison between augmentation with olanzapine and increased risperidone dose in acute schizophrenia patients showing early non-response to risperidone.
Hatta K; Otachi T; Sudo Y; Kuga H; Takebayashi H; Hayashi H; Ishii R; Kasuya M; Hayakawa T; Morikawa F; Hata K; Nakamura M; Usui C; Nakamura H; Hirata T; Sawa Y;
Psychiatry Res; 2012 Jul; 198(2):194-201. PubMed ID: 22421064
[TBL] [Abstract][Full Text] [Related]
12. Effect of risperidone metabolism and P-glycoprotein gene polymorphism on QT interval in patients with schizophrenia.
Suzuki Y; Tsuneyama N; Fukui N; Sugai T; Watanabe J; Ono S; Saito M; Inoue Y; Someya T
Pharmacogenomics J; 2014 Oct; 14(5):452-6. PubMed ID: 24589909
[TBL] [Abstract][Full Text] [Related]
13. Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina.
Sacristán JA; Gómez JC; Montejo AL; Vieta E; Gregor KJ
Clin Ther; 2000 May; 22(5):583-99. PubMed ID: 10868556
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis.
Czekalla J; Beasley CM; Dellva MA; Berg PH; Grundy S
J Clin Psychiatry; 2001 Mar; 62(3):191-8. PubMed ID: 11305706
[TBL] [Abstract][Full Text] [Related]
15. Optimal Dosing of Risperidone and Olanzapine in the Maintenance Treatment for Patients With Schizophrenia and Related Psychotic Disorders: A Retrospective Multicenter Study.
Yoshimura Y; Takeda T; Kishi Y; Harada T; Nomura A; Washida K; Yoshimura B; Sato K; Yada Y; Aoki S
J Clin Psychopharmacol; 2017 Jun; 37(3):296-301. PubMed ID: 28306616
[TBL] [Abstract][Full Text] [Related]
16. Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia.
Lang DJ; Kopala LC; Vandorpe RA; Rui Q; Smith GN; Goghari VM; Lapointe JS; Honer WG
Am J Psychiatry; 2004 Oct; 161(10):1829-36. PubMed ID: 15465980
[TBL] [Abstract][Full Text] [Related]
17. [Incidence of extrapyramidal symptoms during treatment with olanzapine, haloperidol and risperidone: results of an observational study].
Sacristán JA; Gómez JC; Ferre F; Gascón J; Pérez Bravo A; Olivares JM
Actas Esp Psiquiatr; 2001; 29(1):25-32. PubMed ID: 11333516
[TBL] [Abstract][Full Text] [Related]
18. QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia.
Ozeki Y; Fujii K; Kurimoto N; Yamada N; Okawa M; Aoki T; Takahashi J; Ishida N; Horie M; Kunugi H
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Mar; 34(2):401-5. PubMed ID: 20079791
[TBL] [Abstract][Full Text] [Related]
19. Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in Japan.
Ye W; Fujikoshi S; Nakahara N; Takahashi M; Ascher-Svanum H; Ohmori T
Psychiatry Clin Neurosci; 2012 Jun; 66(4):313-21. PubMed ID: 22624736
[TBL] [Abstract][Full Text] [Related]
20. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
